Since remdesivir is currently under emergency use authorization, its safety profile has not yet been fully characterized. A randomized, blinded, placebo-controlled, phase I study evaluating the tolerability and safety profile of single-dose and multiple-dose remdesivir compared to placebo in healthy subjects reported that remdesivir was well tolerated in both subjects study groups with no serious adverse effects or associated mortality.

- **Cardiovascular**: Hypotension, arrhythmias, and cardiac arrest

- **Pulmonary:**Dyspnea, Acute respiratory failure, acute respiratory distress, pneumothorax, pulmonary embolism

- **Hematological:**Anemia, lymphopenia

- **Endocrine**: Hyperglycemia

- **Infectious**: Pneumonia, septic shock

- **Gastrointestinal:**elevated lipase, nausea, vomiting, diarrhea, constipation, poor appetite, gastroparesis, and lower GI bleeding

- **Hepatic:**Hepatic manifestation characterized by Grade 1-4 increase in serum transaminases (ALT and/or AST) are the most common adverse effects in patients treated with remdesivir. Other abnormalities include hyperbilirubinemia

- **Renal and Metabolic:**Acute kidney injury or worsening of underlying chronic kidney disease, hypernatremia, hypokalemia

- **Neurological**: Headache, lightheadedness

- **Skin:**Rash, contact dermatitis, pruritus

- **Psychiatric**: Delirium

- **Other adverse effects:**Pyrexia, insomnia,multi-organ dysfunction, DVT, and hypersensitivity/anaphylactic reactions related to the infusion

The above list was compiled from the results of various clinical trials.